IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast
Gothenburg, Sweden, August 20, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – June 2026. The interim report will be published on Wednesday, August 26, 2026, at 07:00 CEST.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
CEO interview with Kristina Torfgård and CFO Gustaf Albèrt at Redeye
Redeye interviewed CEO Kristina Torfgård and CFO Gustaf Albèrt about IRLAB’s announced rights issue and the company’s priorities going forward. Published on June 16, 2026. Watch the video on Vimeo
Read More >